{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T13:47:41Z","timestamp":1725284861647},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>The immune system is extremely important in the development and progression of Merkel cell carcinoma (MCC). Immune checkpoint blockade has recently been shown to enable efficacious treatment of a variety of tumours. We report the use of an anti-programmed death receptor 1 (PD-1) antibody for treatment of a patient with metastatic MCC. An 80-year-old patient with metastatic MCC received off-label treatment with the anti-PD-1 antibody pembrolizumab after the disease had progressed during therapy with oral etoposide. A positron emission tomography (PET) computed tomography scan performed after three cycles of pembrolizumab revealed responses to therapy with reduced size of the adrenal gland metastases and less PET activity in the adrenal gland and lymph node metastases. Treatment was resumed owing to disease progression after a treatment-free interval of &amp;gt; 4 months. During subsequent months of treatment, the size of the metastases stabilized and uptake of nuclide by all tumour sites once again decreased. These results reveal the potential efficacy of an anti-PD-1 antibody for treatment of metastatic MCC. Thus, they contribute to currently limited data on the use of anti-PD-1 antibodies for the treatment of MCC. Moreover, this is the first report of successful resumption of treatment of metastatic MCC with an anti-PD-1 antibody. Results from ongoing trials will contribute to determination of the relevance of PD-1 blockade in metastatic MCC.<\/jats:p>","DOI":"10.1111\/bjd.14632","type":"journal-article","created":{"date-parts":[[2016,4,2]],"date-time":"2016-04-02T19:18:02Z","timestamp":1459624682000},"page":"216-219","source":"Crossref","is-referenced-by-count":21,"title":["PD-1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma"],"prefix":"10.1093","volume":"176","author":[{"given":"J.K.","family":"Winkler","sequence":"first","affiliation":[{"name":"Department of Dermatology and National Center for Tumor Diseases (NCT) University Hospital Heidelberg Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bender","sequence":"additional","affiliation":[{"name":"Department of Dermatology and National Center for Tumor Diseases (NCT) University Hospital Heidelberg Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kratochwil","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Enk","sequence":"additional","affiliation":[{"name":"Department of Dermatology and National Center for Tumor Diseases (NCT) University Hospital Heidelberg Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.C.","family":"Hassel","sequence":"additional","affiliation":[{"name":"Department of Dermatology and National Center for Tumor Diseases (NCT) University Hospital Heidelberg Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,1,1]]},"reference":[{"key":"2023011316201511200_bjd14632-bib-0001","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3390\/cancers6021180","article-title":"Systemic therapy for Merkel cell carcinoma: what's on the horizon?","volume":"6","author":"Rabinowits","year":"2014","journal-title":"Cancers (Basel)"},{"key":"2023011316201511200_bjd14632-bib-0002","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00104-010-2066-4","article-title":"Merkel cell carcinoma: a highly aggressive tumor with possible viral etiology","volume":"82","author":"Toberer","year":"2011","journal-title":"Chirurg"},{"issue":"Suppl. 5","key":"2023011316201511200_bjd14632-bib-0003","doi-asserted-by":"crossref","first-page":"9091","DOI":"10.1200\/jco.2014.32.15_suppl.9091","article-title":"Response rate and durability of chemotherapy for metastatic Merkel cell carcinoma among 62 patients","volume":"32","author":"Iyer","year":"2014","journal-title":"J Clin Oncol"},{"key":"2023011316201511200_bjd14632-bib-0004","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1126\/science.1152586","article-title":"Clonal integration of a polyomavirus in human Merkel cell carcinoma","volume":"319","author":"Feng","year":"2008","journal-title":"Science"},{"key":"2023011316201511200_bjd14632-bib-0005","doi-asserted-by":"crossref","first-page":"dju422","DOI":"10.1093\/jnci\/dju422","article-title":"Merkel cell carcinoma and immunosuppression: what we still need to know","volume":"107","author":"Locke","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2023011316201511200_bjd14632-bib-0006","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2023011316201511200_bjd14632-bib-0007","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1517\/14712598.2013.770836","article-title":"Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy","volume":"13","author":"Hamid","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"2023011316201511200_bjd14632-bib-0008","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2023011316201511200_bjd14632-bib-0009","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2326-6066.CIR-13-0034","article-title":"PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival","volume":"1","author":"Lipson","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"2023011316201511200_bjd14632-bib-0010","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1158\/1078-0432.CCR-13-0035","article-title":"Merkel polyomavirus-specific T cells fluctuate with Merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers","volume":"19","author":"Afanasiev","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2023011316201511200_bjd14632-bib-0011","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"2023011316201511200_bjd14632-bib-0012","doi-asserted-by":"crossref","volume-title":"Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma","author":"Nghiem","DOI":"10.1016\/S0959-8049(15)30074-5"},{"key":"2023011316201511200_bjd14632-bib-0013","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2023011316201511200_bjd14632-bib-0014","volume-title":"Avelumab in subjects with Merkel cell carcinoma","author":"EMD Serono"},{"key":"2023011316201511200_bjd14632-bib-0015","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1158\/1078-0432.CCR-12-2625","article-title":"Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody","volume":"19","author":"Lipson","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2023011316201511200_bjd14632-bib-0016","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/cancers5010234","article-title":"The role of the immune response in Merkel cell carcinoma","volume":"5","author":"Triozzi","year":"2013","journal-title":"Cancers (Basel)"},{"key":"2023011316201511200_bjd14632-bib-0017","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/jid.2013.75","article-title":"Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses","volume":"133","author":"Dowlatshahi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2023011316201511200_bjd14632-bib-0018","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2010.30.6308","article-title":"Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival","volume":"29","author":"Paulson","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.14632","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.14632","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.14632","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjd.14632","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/176\/1\/216\/48702984\/bjd0216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/176\/1\/216\/48702984\/bjd0216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:20:24Z","timestamp":1676384424000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/176\/1\/216\/6747916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,1]]},"published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.14632","relation":{},"ISSN":["1365-2133","0007-0963"],"issn-type":[{"value":"1365-2133","type":"electronic"},{"value":"0007-0963","type":"print"}],"subject":[],"published-other":{"date-parts":[[2017,1,1]]},"published":{"date-parts":[[2017,1,1]]}}}